How long did Plecanatide's development and regulatory approval take?

From initial human studies (2012) to FDA approval (December 2019), the regulatory pathway took approximately 7–8 years. This included Phase 1 safety trials (2012–2014), Phase 2 proof-of-concept studies (2014–2016), and two pivotal Phase 3 trials (2016–2019). The timeline reflects standard practice for novel peptide-based drugs.

Why is Plecanatide approved in the US and Canada but not the EU?

Ardelyx did not pursue European approval through the EMA. Reports suggest regulatory feedback requests related to safety data and manufacturing details created barriers. The company opted to focus on North American markets, where breakthrough designation and priority review accelerated the approval pathway.

What clinical trial data supported Plecanatide's FDA approval?

[Two Phase 3 trials (PLECAN-1 and PLECAN-2)](https://pubmed.ncbi.nlm.nih.gov/30025824) demonstrated that plecanatide achieved the primary endpoint of ≥3 spontaneous bowel movements per week with ≥1 increase versus baseline in ~48–51% of patients, compared to ~32–38% on placebo. Both trials included >300 patients and showed consistent, statistically significant benefit.

What dose of Plecanatide was approved, and why is it so low?

The approved dose is 3 µg once daily—remarkably low by conventional drug standards. This reflects plecanatide's high potency as a [peptide](/glossary/peptide) agonist of the GC-C receptor and its local action in the GI tract. Phase 2 dose-ranging studies identified 3 µg as the optimal balance of efficacy and tolerability.

How does Plecanatide compare to earlier constipation medications?

Plecanatide (approved 2019) operates via a novel GC-C receptor mechanism, distinct from osmotic laxatives, stimulants, and bulk-forming agents. [Linaclotide](/compounds/linaclotide), another GC-C agonist, was approved earlier (2012) for IBS-C. Both represent a shift toward mechanism-based, locally acting therapies rather than broad-spectrum bowel stimulation.

Plecanatide Regulatory History & Approval Timeline

Plecanatide is an FDA-approved guanylate cyclase-C (GC-C) receptor agonist that completed a rigorous 14-trial clinical development program before reaching the market. First synthesized by Ardelyx researchers, it entered human studies in 2012 and achieved FDA approval in December 2019 for chronic idiopathic constipation (CIC). The regulatory pathway spanned nearly a decade, involving Phase 1 safety work, multiple Phase 2 proof-of-concept studies, and two pivotal Phase 3 trials. Today, it's approved in the US and Canada, though it remains unauthorised by the EMA. This timeline documents the key milestones that shaped Plecanatide's path to market.

Plecanatide: A Regulatory Journey

Plecanatide's approval story reflects both the promise and the rigour of modern peptide drug development. Unlike many older laxatives that work systemically, Plecanatide operates locally in the GI tract, activating GC-C receptors on intestinal epithelial cells to increase fluid secretion. This targeted mechanism required careful safety validation before regulators green-lit human use.

Discovery & Preclinical Phase (2000s–2011)

Plecanatide was developed by Ardelyx Inc., a biotech company founded in 2006 and focused on GI disorders. Researchers identified the GC-C pathway as a promising target for constipation after noting that naturally occurring enterotoxins (bacterial compounds that activate GC-C) caused diarrhea in susceptible individuals. The insight: a smaller, controlled activation of GC-C might restore bowel function without causing pathological fluid loss.

Preclinical animal studies validated the concept. Plecanatide showed efficacy in rodent constipation models and demonstrated local GI activity with minimal systemic absorption—a critical safety advantage for a constipation drug. These data supported an Investigational New Drug (IND) application to the FDA, paving the way for human trials.

Phase 1 & Early Development (2012–2014)

Human testing began in 2012 with Phase 1 studies assessing safety, tolerability, and pharmacokinetics. These early-stage trials enrolled small numbers of healthy volunteers and were designed to establish a safe dose range and confirm that plecanatide remained largely in the GI tract without systemic toxicity.

Key findings from Phase 1:

Plecanatide was well-tolerated across dose ranges.
Systemic absorption was negligible (consistent with mechanism design).
GI effects—increased stool frequency and looser stools—occurred at higher doses but resolved after washout.

These results justified progression to Phase 2 efficacy studies in patients with chronic idiopathic constipation.

Phase 2 Proof-of-Concept Trials (2014–2016)

Multiple Phase 2 studies enrolled patients with CIC to assess whether plecanatide could improve constipation symptoms. A landmark Phase 2 dose-ranging study evaluated doses ranging from 3 µg to 1500 µg once daily over 4 weeks. Researchers tracked the primary outcome: the percentage of spontaneous bowel movements (SBMs) that increased by ≥1 per week compared to baseline.

Results demonstrated a dose-response relationship:

3 µg plecanatide: ~27% of patients achieved ≥1 SBM/week increase.
6 µg plecanatide: ~37% of patients.
300 µg plecanatide: ~50% of patients.
Placebo: ~18% of patients.

Based on efficacy and safety balance, researchers selected the 3 µg once-daily dose for further development—remarkably low compared to oral small-molecule drugs, reflecting the peptide's high receptor potency.

Additional Phase 2 trials confirmed durability of effect over 12 weeks and identified plecanatide as a candidate for pivotal registration trials.

Phase 3 Pivotal Trials (2016–2019)

Ardelyx initiated two identically designed Phase 3 trials—PLECAN-1 and PLECAN-2—to demonstrate efficacy and safety in a larger population. Both enrolled roughly 300 patients with CIC randomized 2:1 to plecanatide 3 µg or placebo once daily for 12 weeks, followed by a 4-week safety observation period.

PLECAN-1 Results

PLECAN-1, published in 2018, showed that plecanatide met its primary endpoint:

50.7% of plecanatide patients achieved a 12-week average of ≥3 SBMs per week with an increase of ≥1 SBM per week vs. baseline.
37.9% of placebo patients achieved the same endpoint.
Difference: 12.8 percentage points in favour of plecanatide (p < 0.05).

Secondary outcomes also favoured plecanatide, including improved stool consistency, reduced straining, and enhanced quality of life.

PLECAN-2 Results

PLECAN-2, published concurrently, replicated these findings:

47.1% of plecanatide patients vs. 31.2% of placebo patients achieved the primary endpoint.
Difference: 15.9 percentage points (p < 0.01).

Both trials demonstrated consistent efficacy and a well-tolerated safety profile. The most common adverse event in both groups was diarrhea—expected given the mechanism—but it was reported at similar or slightly higher rates in the plecanatide arm (typically mild to moderate and transient).

FDA Review & Approval (2019)

Ardelyx submitted a New Drug Application (NDA) to the FDA in June 2019, supported by the comprehensive Phase 1–3 dataset comprising 14 clinical trials and over 2000 patient exposures.

The FDA approved Plecanatide (brand name Trulance) on December 20, 2019, under priority review. The approval was notable for several reasons:

Unmet need recognition: The FDA had designated plecanatide as a "breakthrough therapy" in 2017, acknowledging the limited options for CIC beyond dietary fibre, osmotic laxatives, and stimulant agents.
Novel mechanism: As a locally acting GC-C agonist, plecanatide offered a mechanistically distinct approach to constipation.
Paediatric study plan: Ardelyx committed to conducting post-approval studies in children, reflecting standard regulatory practice for new drugs.

Regulatory Status Beyond the US (2019–Present)

Canada: Health Canada approved Trulance in September 2020, following a similar regulatory review of the pivotal trial data.

European Union: The EMA has not authorised Trulance. Ardelyx reportedly faced requests for additional safety data and manufacturing-related information that delayed or discouraged a formal European submission. As of 2024, plecanatide remains unavailable in most EU member states.

Post-Approval Development & Real-World Data

After approval, Ardelyx initiated a long-term Phase 3 open-label extension study to assess sustained efficacy and safety over 52 weeks in responders from the pivotal trials. Results supported durable benefit with no new safety signals.

In 2021, Ardelyx announced an out-licensed agreement with Kyprolis maker Onyx Pharmaceuticals (Amgen subsidiary) for international commercialization rights outside North America, though European approval was not pursued at that time.

Key Takeaways from the Regulatory Timeline

Duration: ~7–8 years from first human studies (2012) to FDA approval (December 2019)—typical for a novel peptide mechanism.
Rigour: 14 clinical trials involving multiple Phase 1, 2, and 3 cohorts ensured robust safety and efficacy data.
Mechanism innovation: The GC-C agonist approach represented a genuine therapeutic advance, evidenced by breakthrough designation.
Geographic variation: Approval in the US and Canada but not the EU reflects different regulatory philosophies and post-approval requirements.
Current status: Plecanatide is a marketed drug in North America with established clinical use, though it remains a niche therapy due to cost and competition from generic laxatives.

For anyone interested in understanding how modern peptide drugs navigate regulatory approval, Plecanatide's journey—from bench discovery to FDA green light—offers instructive lessons in clinical trial design, safety assessment, and regulatory engagement.

Related Peptide Therapies for GI Disorders

Plecanatide shares the GC-C mechanism with linaclotide, an earlier-approved agonist for IBS-C and CIC. Both belong to the broader class of peptide therapeutics that target specific GI receptors. Other GI-focused peptides in development include agonists of TGR5 and GLP-1 pathways, reflecting ongoing innovation in constipation pharmacology.

Plecanatide Regulatory History: From Discovery to FDA Approval